BUZZ-Chimerix Inc: Shares slump after Ebola patient dies

Wed Oct 8, 2014 11:48am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]


** Drug developer's shares down 12 pct at $29.00, snapping a sharp 6-day rally, after first Ebola patient diagnosed in the United States dies

** Thomas Eric Duncan was being treated with Chimerix's antiviral drug, brincidofovir

** Stock had earlier risen as much as 8 percent to a record high of $35.98 after the company said the drug showed promise for a respiratory ailment

** Canadian drugmaker Tekmira Pharmaceuticals Corp's U.S.-listed shares up about 3 pct. A U.S. aid worker treated received the company's treatment, TKM-Ebola, last month

** Sarepta Therapeutics Inc's shares fall 4 pct. The company is also developing an Ebola treatment

** More than 7 million Chimerix shares traded as of 1129 ET, more than four times their 10-day average volume

** Earlier on Wednesday, Piper Jaffray raised price target on stock to $41 from $37 and Stifel Nicolaus to $47 from $34

** Stock had risen nearly 11 pct in the past two days after the company said on Monday that brincidofovir could potentially be used on Ebola patients (Reuters Messaging: